复发性妇科恶性肿瘤的微创脾切除术及长期结局
回顾性单中心队列研究纳入10例铂敏感复发性妇科恶性肿瘤(6例卵巢、2例子宫内膜、2例宫颈)累及脾或左上腹的患者,行微创脾切除术(腹腔镜6例、机器人4例),全部无中转开腹,术后并发症均为Clavien-Dindo I-II级,R0切除率100%。在8例病理确诊妇科恶性肿瘤患者中,中位随访53.8个月,5年总生存率和无病生存率均为100%(精确95%CI 39.8%-100%)。
要点
- 微创脾切除术在该高度选择队列中技术上可行,无中转开腹。
- 术后并发症限于Clavien-Dindo I-II级,中位住院42小时。
- 8例确诊患者5年OS和DFS均为100%,但样本量小需谨慎解读。
核心结论
- 在该高度选择的三级转诊中心队列中,微创脾切除术技术上可行、短期安全,并观察到有利的肿瘤学结局。
- 这些发现支持可行性,但不能确立因果性的肿瘤学疗效。
研究设计与样本
- 回顾性单机构队列研究(AAGL证据分类II-3),设置于三级学术转诊中心(Mayo Clinic, AZ)。
- 纳入10例连续铂敏感复发性妇科恶性肿瘤累及脾或左上腹的患者(6例卵巢、2例子宫内膜、2例宫颈)。
- 8例病理确诊复发性妇科恶性肿瘤,2例病理为非妇科疾病(坏死性肉芽肿;B细胞淋巴瘤),主要肿瘤学分析限于8例确诊患者。
- 干预为微创脾切除术(腹腔镜6例、机器人4例)用于二次或三次减瘤,必要时行伴随手术以完整切除。
主要发现
- 所有手术均微创完成,无中转开腹。
- 中位手术时间202分钟(IQR 196.5-211.5;范围108-325),中位估计出血量50 mL(IQR 50-125;范围20-450)。
- 无术中并发症;术后并发症限于Clavien-Dindo I-II级,中位综合并发症指数11.2;中位住院42小时(IQR 25.5-72.25)。
- R0切除10/10例(100%)。
- 在主要分析(n=8)中,脾切除后中位随访53.8个月,1例在78.5个月复发,无患者死亡;5年总生存率和5年无病生存率均为100%(精确95%CI 39.8%-100%)。
关键数值与推荐
- R0切除率100%(10/10)。
- 术后并发症仅Clavien-Dindo I-II级,中位综合并发症指数11.2。
- 中位住院42小时(IQR 25.5-72.25)。
- 8例确诊患者5年OS和DFS均为100%(精确95%CI 39.8%-100%)。
临床怎么用
- 对于高度选择的铂敏感复发性妇科恶性肿瘤累及脾或左上腹患者,微创脾切除术可作为二次或三次减瘤的可行选项。
- 需由经验丰富的三级转诊中心团队实施,并注意样本量小、选择偏倚大,不能据此推断肿瘤学疗效。
局限性
- 回顾性单机构小样本队列(n=10,主要分析n=8),选择偏倚大。
- 生存估计因样本量小需谨慎解读,精确95%CI宽(39.8%-100%)。
- 研究设计不能确立因果性肿瘤学疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: To evaluate the surgical safety, feasibility, and long-term oncologic outcomes of minimally invasive (MIS) splenectomy in patients with isolated or oligometastatic recurrence of gynecologic malignancies. DESIGN: Retrospective single-institution cohort study (AAGL Classification of Evidence: II-3). SETTING: Tertiary academic referral center (Mayo Clinic, AZ). PATIENTS: Ten consecutive women with platinum-sensitive recurrent gynecologic cancer (6 ovarian, 2 endometrial, 2 cervical) involving the spleen or left upper quadrant. Eight patients had pathologically confirmed recurrent gynecologic malignancy; in 2, pathology revealed nongynecologic disease (necrotizing granuloma; B-cell lymphoma). The primary oncologic analysis was restricted to the 8 confirmed cases. INTERVENTIONS: MIS splenectomy (laparoscopic, n = 6; robotic, n = 4) for secondary or tertiary cytoreduction, with concomitant procedures when needed for complete resection. MEASUREMENTS AND MAIN RESULTS: All procedures were completed minimally invasively without conversion. Median operative time was 202 minutes (IQR 196.5-211.5; range 108-325) and median estimated blood loss was 50 mL (IQR 50-125; range 20-450). No intraoperative complications occurred. Postoperative complications were limited to Clavien-Dindo grade I to II; median Comprehensive Complication Index was 11.2. Median hospital stay was 42 hours (IQR 25.5-72.25). R0 resection was achieved in 10/10 patients (100%). In the primary analysis (n = 8), at a median follow-up of 53.8 months after splenectomy, 1 patient developed recurrence at 78.5 months and no patient had died; 5-year overall survival and 5-year disease-free survival were both 100% (exact 95% CI 39.8%-100%). Survival estimates should be interpreted cautiously given the small sample size. CONCLUSION: In this highly selected cohort treated at a tertiary referral center, MIS splenectomy appeared technically feasible and short-term safe and was associated with favorable observed oncologic outcomes. These findings support feasibility but do not establish causal oncologic efficacy.
引用
- Erdemoglu E, Schaeffeler HJ, Magtibay PM, et al. Minimally Invasive Splenectomy for Recurrent Gynecologic Cancer and Long-Term Outcomes. J Minim Invasive Gynecol. 2026. PMID: 42632538. doi:10.1016/j.jmig.2026.08.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。